Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5267394
Max Phase: Preclinical
Molecular Formula: C11H9N3O
Molecular Weight: 199.21
Associated Items:
ID: ALA5267394
Max Phase: Preclinical
Molecular Formula: C11H9N3O
Molecular Weight: 199.21
Associated Items:
Canonical SMILES: Cn1c(=O)c2cncn2c2ccccc21
Standard InChI: InChI=1S/C11H9N3O/c1-13-8-4-2-3-5-9(8)14-7-12-6-10(14)11(13)15/h2-7H,1H3
Standard InChI Key: DRDQDSHUTDDSSI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 199.21 | Molecular Weight (Monoisotopic): 199.0746 | AlogP: 1.19 | #Rotatable Bonds: 0 |
Polar Surface Area: 39.30 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 1.67 | CX LogP: 0.64 | CX LogD: 0.64 |
Aromatic Rings: 3 | Heavy Atoms: 15 | QED Weighted: 0.55 | Np Likeness Score: -0.87 |
1. Károlyi BI, Potor A, Kapus GL, Fodor L, Bobok A, Krámos B, Magdó I, Bata I, Szabó G.. (2023) Novel imidazo[1,5-a]quinoxaline derivatives: SAR, selectivity and modeling challenges en route to the identification of an α5-GABAA receptor NAM., 80 [PMID:36549396] [10.1016/j.bmcl.2022.129107] |
Source(1):